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Abstract 
Objective:  Methotrexate is routinely used worldwide for medical treatment of clinically 
stable women with tubal ectopic pregnancies.  This is despite the lack of robust 
evidence to show its superior effectiveness over expectant management. The aim of our 
multicentre randomised trial study was to compare the success rates of methotrexate 
with placebo for the conservative treatment of tubal ectopic pregnancies. 
Methods: The study was multicentre; it took place in three UK early pregnancy units 
between January 2006 and June 2014. Inclusion criteria were clinically stable women 
with a conclusive ultrasound diagnosis of a tubal ectopic pregnancy presenting with low 
serum β-hCG <1500IU/l. Women were randomly assigned to single systemic injection 
of methotrexate 50mg/m2 or placebo.  The primary outcome of the study was a binary 
indicator for success of conservative management, defined as resolution of clinical 
symptoms and decline of serum β-hCG to <20IU/l or negative urine pregnancy test 
without the need for any additional medical intervention. An intention to treat analysis 
was followed. 
Results: We recruited a total of 80 women: 42 to methotrexate and 38 to placebo. The 
two arms of the study were balanced in terms of age, ethnicity, obstetric histories, 
pregnancy characteristics and serum β-hCG and progesterone.  The proportions of 
successes were similar:  83% with methotrexate and 76% with placebo. On univariate 
analysis, this difference was not statistically significant (χ2(1df) = 0.53; P=0.23).  
On multivariate logistic regression, β-hCG was the only covariate which was 
significantly associated with outcome.  The odds of failure increased by 0.15% for each 
unit increase in β-hCG (OR=1.0015; 95% CI 1.0002 to 1.003; P=0.02). In 14 women 
presenting with serum hCG 1000-1500IU/l the success of expectant management was 
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33% compared to 62% in the methotrexate arm. Although this result was not 
statistically significant a larger sample size would give us greater power to detect a 
difference in this subgroup of women, 
In women with successful conservative management there was no significant difference 
in median resolution times between methotrexate and placebo arms [17.5 days (IQR 14 
- 28.0) (n=30)] vs [14 days (IQR 7 - 29.5) (n=25)] (P= 0.73) 
Conclusion:  The results of our study do not support routine use of methotrexate for the 
treatment of clinically stable women diagnosed with tubal ectopic pregnancies 
presenting with low serum hCG <1500IU/l. Further work is required to identify a 
subgroup of women with tubal ectopic pregnancies and hCG≥1500IU/l in whom 
methotrexate may offer a safe and cost-effective alternative to surgery. 
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Introduction 
 
Ectopic pregnancy is a common condition which affects 1% to 2% of pregnant women 
worldwide.  Although fatalities are rare with ectopic pregnancies in developed 
countries1, the burden of disease is high owing to costs of diagnostic work up and 
expensive treatment. A recent NICE guideline on the diagnosis and management of 
early pregnancy complications stipulates that all women diagnosed with ectopic 
pregnancies should be managed actively either using medical treatment with 
methotrexate or surgery2. Although clinically stable women who present with small 
ectopics and low serum β-hCG levels are sometimes managed expectantly in clinical 
practice, there is limited data on the efficacy and safety of this approach.  In a Cochrane 
Collaboration’s review only two randomised trials comparing expectant with medical 
management were identified3.  Women in the treatment arm of the first trial were given 
an oral dose of methotrexate4, whilst systemic prostaglandins were used in the second 
trial5; neither of these is used in standard clinical practice.  A more recent systematic 
review and meta-analysis on the treatment of tubal ectopic pregnancies emphasised the 
need for more research to be done in assessing the feasibility of expectant management 
in women presenting with serum β-hCG levels <1500IU/l6.   
Several observational studies showed a high success of expectant management in 
selected groups of women with small tubal ectopic pregnancies7-9.  Expectant 
management follows natural history of the condition and it avoids the risks associated 
with surgical and medical management. This makes it attractive to pregnant women and 
its uptake is high when offered as one of the available management options10. In the last 
two years, two randomised trials comparing expectant management with systemic 
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methotrexate have been published11,12. One of these was very small whilst the other 
mainly included women with pregnancies of unknown location.  This suggests that 
more robust evidence is needed to determine the role of expectant management in tubal 
ectopic pregnancies.  
The aim of this placebo-controlled randomised trial was to assess whether medical 
treatment with methotrexate is more successful than expectant management in clinically 
stable women presenting with tubal ectopic pregnancies and serum hCG <1500IU/l.  
 
Methods 
Study design  
This was a multicentre randomized controlled trial which was carried out in three UK 
teaching hospitals form August 2005 to June 2014.   
 
Study population 
All clinically stable women with a conclusive ultrasound diagnosis of a tubal ectopic 
pregnancy13 were eligible for the trial. The other inclusion criteria were the absence of 
embryonic heart rate and haemoperitoneum on ultrasound scan, initial serum β-hCG 
<1500IU/l, normal full blood count, liver and renal function tests and no history of 
hepatic, renal or pulmonary disease.   
 
Ethical approval 
The trial was conducted in compliance with the principles of the Declaration of Helsinki 
(1996), the principles of Good Clinical Practice and all of the applicable regulatory 
requirements including Research Governance Framework and the Medicines for Human 
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Use (Clinical Trial) Regulations.  The trial protocol was reviewed and approved by the 
Royal Free Hospital Medical School Research Ethics Committee and by the Medicines 
and Healthcare Products Regulatory Agency (MHRA). The trial was registered as an 
International Standard Randomised Clinical Trial (ISRCTN95698259). 
 
Study treatment 
Women who consented to participate in the study were randomly assigned to 
methotrexate treatment or placebo. A computer-generated simple randomization list was 
used and the allocation sequence was kept at the King’s College Hospital pharmacy, 
blinded to the recruiters or to local pharmacies staff. Upon receipt of the Patient 
Randomisation Request Form from a local hospital pharmacy, a designated pharmacist 
at King’s College Hospital referred to the sequence to identify the next eligible patient 
randomization number. Local pharmacies were then instructed to prepare trial 
medication as appropriate.   
Women allocated to methotrexate treatment received a single gluteal intramuscular 
injection of methotrexate 50mg/m2 (Methotrexate injection PL 25215/0014; Hameln 
Pharma Plus GMBH, Langes Feld 13, 31789 Hameln, Germany). Women allocated to 
placebo were given a gluteal intramuscular injection of 0.9% solution of sodium 
chloride (Sodium Chloride 0.9% injection PL 24598/0002; Fannin, Pincents Kiln 
Industrial Park, Calcot, Reading). Both placebo and methotrexate were labelled and 
distributed by Guy’s and St Thomas’ Pharmacy Manufacturing, London, UK. To 
maintain blinding for the study, the trial medication prepared by pharmacy was kept in a 
sealed opaque bag.  Syringes containing trial medication were kept out of women’s 
view and the medication was administered only by trained nurses or doctors who were 
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independent from the trial. They were given clear instructions not to discuss with 
women possible treatment allocation or any other aspect of the study. The 
administration of trial medication was documented and the prescription sheet was given 
to the investigator to keep with other trial documents. 
All women were given trial medication within 24 hours of the initial visit which was 
labelled as Day 1. They attended for follow up visits on days 4 and 7 when a blood 
sample was taken to measure serum β-hCG levels. Full blood count, liver and renal 
function tests were also checked on day 7.  A visit window of +/- 1 day was considered 
acceptable for follow up visits. 
All women were advised against long distance travel and they were advised to refrain 
from sexual intercourse. They were provided with a 24 hour contact number and 
advised to return to hospital should they experience any significant increase in 
abdominal pain. Women were also advised to increase their fluid intake and avoid 
exposure to sunlight. They were also informed of common side effects of methotrexate 
and advised to avoid alcohol, non-steroidal anti-inflammatory drugs and aspirin. The 
treatment was classified as unsuccessful and women were offered surgery if serum β-
hCG levels increased by >15% on two consecutive visits. Surgery was also advised in 
women who developed abdominal pain with evidence of haemoperitoneum on 
ultrasound scan. When β-hCG fell by >15%, weekly blood tests were arranged until it 
reached a level <20IU/L. In women with static serum β-hCG (within ± 15% of the 
previous reading) blood tests were arranged every two days to ensure that the levels 
were not increasing. 
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Outcome measures 
The primary outcome of the study was a binary indicator of success of conservative 
management    defined in terms of the resolution of clinical symptoms and decline of 
serum β-hCG to <20IU/l or negative urine pregnancy test without the need for any 
additional medical intervention. The secondary outcomes were the proportion of women 
suffering severe intra-abdominal bleeding requiring blood transfusion, number of 
emergency laparotomies, proportion of women experiencing significant pelvic pain or 
gastro-intestinal side effects and the serum β -hCG resolution times.  
 
Statistical methodology 
 We aimed to detect a reduction in the surgical intervention rate from 40% to 12%.  
These were respective contemporaneous surgical intervention rates in women managed 
expectantly and medically in King’s Early Pregnancy Unit. Using these figures, 70 
patients were needed for the study, 35 in each arm to guarantee a power of 80%.  
A pre-specified interim analysis using double triangle stopping boundary14 was carried 
out when 34 women had been recruited which showed a very small difference between 
the two treatments.  The median unbiased estimate of the log odds ratio was 0.13 (95% 
CI -1.96 to 2.2) which did not cross the stopping boundary and a decision was made to 
continue with recruitment. 
 We performed the primary analysis by intention to treat and secondary analysis per 
protocol. We used χ2 tests to assess the significance of the difference in proportions of 
success between the two treatment groups (active vs. placebo). We used logistic 
regression to model the likelihood of success in terms of treatment and other co-
variates. A stepwise approach was followed, with multivariate models adjusting for 
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those covariates that showed significance below 25% in the univariate models. Final 
statistical significance was judged at the 5% level. 
The analysis approach was on an intention to treat for the primary outcome. Two-
sample univariate tests (Mann-Whitney, t-tests or the appropriate χ2 tests) were planned 
to assess if the treatments were balanced at baseline and logistic regressions to model 
the likelihood of success or failure in terms of treatment and other covariates.  
 
 
Results 
We recruited a total of 80 women 42 of whom were allocated to single dose systemic 
methotrexate and 38 to placebo. (Fig. 1) Nine women declined trial intervention after 
randomisation: six in the methotrexate and three in the placebo group. They were all 
managed expectantly. One women in the methotrexate did not attend for any follow up 
visits and she was excluded from the analysis. Baseline characteristics of all women are 
presented in Table 1 which shows that the two groups were reasonable well balanced in 
terms of age, ethnicity, obstetric histories, pregnancy characteristics and serum β-hCG 
and progesterone. 
Primary and secondary outcomes in all women recruited to the trial are shown in Table 
2.  Increasing abdominal pain and suspicion of intra-abdominal bleeding was the main 
reason for surgical intervention followed by rise in serum β-hCG. No woman required 
emergency open surgery (laparotomy) and only one woman (in the placebo group) had a 
blood transfusion. The diagnosis of tubal ectopic pregnancy was confirmed in all 
women who underwent surgery. 
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The proportion of successes by intention to treat was 83% with methotrexate and 76% 
with placebo. On univariate analysis, this difference was not statistically significant 
(χ2(1df) = 0.53; P=0.23). On univariate logistic regressions, neither of the following 
covariates were found to have a significant association with outcome: maternal age 
(P=0.24), smoking status (P=0.70), parity (P= 0.36), previous miscarriages (P= 0.58), 
ethnicity (P=0.44), previous ectopic (P=0.94), side of ectopic (P=0.86) or baseline 
progesterone (P=0.21). 
On multivariate logistic regression, β-hCG was the only covariate that retained 
significance.  The odds of failure increased by 0.15% for each unit increase in β-hCG 
(OR=1.0015; 95% CI 1.0002 to 1.003; P=0.02). Likewise, the risk of failure increased 
by 0.12% for each unit increase in β-hCG (OR=1.0012; 95% CI 1.000 to 1.002; 
P=0.01). Moreover, the failure rate was significantly higher in the 14 women presenting 
with initial serum β-hCG >1000IU/l (OR=6.2; 95% CI 1.76 to 22; P=0.01) and 
(RR=3.6; 95% CI 1.6 to 8; P=0.002). This effect was similar in both treatment groups, 
as indicated by a non-significant interaction (P=0.50). After adjusting for the effect of 
baseline β-hCG, no significant difference was found between the treatment groups in 
terms of the likelihood of failure in terms of odds ratios (OR=0.59; 95 % CI 0.19 to 1.9; 
P=0.37) or, in terms of relative risks (RR=0.69; 95 % CI 0.31 to 1.6; P=0.70), for 
methotrexate relative to placebo.  
In women with successful conservative management there was no significant difference 
in median resolution times between methotrexate and placebo arms [17.5 days (IQR14 - 
28.0)(n=30)] vs [14 days (IQR 7 - 29.5) (n=25)] (P=0.73). 
The proportion of successes analysing per protocol were methotrexate 89% and placebo 
74%. The difference between methotrexate vs placebo was not statistically significant 
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(χ2=2.4; P=0.12). The relative risk for failure in the methotrexate group relative to 
placebo was 0.40 (95 % CI 0.13 to 1.18).   
 
Discussion  
Our study showed that medical treatment with methotrexate did not contribute 
significantly to the success of conservative management of unruptured tubal ectopic 
pregnancies presenting with low initial serum hCG levels <1500 IU/l. There were no 
significant differences in the secondary outcomes of interest such emergency 
laparotomy and blood transfusion rates either. Our sample size calculation assumed 
28% better treatment success rate in the methotrexate compared to the placebo arm.   
The proportions of patients requiring surgical intervention were lower than the 
proportion upon which we based our power calculation. This was mainly due to higher 
than expected spontaneous resolution rates of ectopic pregnancy in the placebo arm. 
Our study was conceived a while ago and the estimated success rate of expectant 
management was based on the data from the literature available at the time which 
showed a wide range of resolution rates between 7% and 66%9,15 compared to the 
average rate of 88% when systemic methotrexate was used16.  More recent studies 
reported higher success rates of expectant management between 59% and 92%11,12 
which is similar to our findings.  
The strengths of our study are: clear and clinically relevant inclusion criteria, robust 
procedures used to minimise the risk of bias and high rate of follow up. The main 
limitation is the long length of time required to complete the study which was partially 
due to administrative delays caused by the change of the chief investigator and the need 
for a new site initiation. The recruitment in one of the centres was poor which caused 
This article is protected by copyright. All rights reserved.
A
cc
ep
te
d 
A
rti
cl
e
further delays. In addition, we found that the majority of women eligible for inclusion in 
the study had a clear preference for one of the available treatment options and were 
reluctant to accept that the management of their ectopic pregnancy should be decided by 
chance. 
In the methotrexate arm 6/42 (14%) of women declined intervention after randomisation 
compared to 3/38 (8%) in the placebo group. We carried out intention to treat analysis 
and, in view of the relatively small sample size, this relatively high dropout rate reduces 
the power of the study. The intervention rate in the placebo arm of the trial was lower 
than anticipated which also increases the risk of Type II error, 
In 14 women presenting with serum hCG 1000-1500IU/l the success of expectant 
management was 33% compared to 62% in the methotrexate arm. Although this result 
was not statistically significant a larger sample size would give us greater power to 
detect a difference in this subgroup of women, 
Our overall findings; however, are similar to the previously published randomised 
studies comparing methotrexate with placebo in women diagnosed with tubal ectopic 
pregnancies. (Table 3) In the study by Korhonen et al.4 women in the treatment arm 
were prescribed a very low dose of oral methotrexate whilst systemic parenteral route 
was used in the other three trails. In three out of four trials the researches only included 
ectopic pregnancies presenting with serum β-hCG levels <2000IU/l. In the remaining 
study the inclusion criteria allowed randomisation of women presenting with ectopic 
and β-hCG levels <5000IU/l4.  Despite the inclusion criteria being more liberal the 
median initial β-hCG levels in that particular study were slightly lower compared to 
other trials.  
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Three studies only included women with tubal ectopic pregnancies which were 
positively identified on ultrasound scan. In a study by van Mello et al.11 only 20% of 
women were diagnosed with ectopic pregnancies on ultrasound, whilst the remaining 
80% of women had pregnancies of unknown location, most of which are likely to 
represent failed intrauterine pregnancies. They all had plateauing serum β-hCG levels; 
however, which many clinicians feel compelled to treat. 
Study by Silva et al.12 is different form the other three as they only included women 
with ectopic pregnancies and failing serum β-hCG levels. This could explain higher 
success rate in both arms of their trial compared to the other studies.   
Methotrexate is often given to women with ectopic pregnancies or those with 
pregnancies of unknown location in order to shorten the length of follow up and 
expedite clearance of serum β-hCG. We found no significant difference in the length of 
time required for serum β-hCG to return to pre-pregnancy level between the two arms 
of the study.  The other three previous trials4,11,12 have reported similar findings and it is 
safe to conclude that the administration of methotrexate does not result if faster 
resolution of tubal ectopic pregnancies managed conservatively. 
All these findings call for a reassessment of the role of methotrexate as the primary 
treatment of tubal ectopic pregnancy. There is a possibility that its future use may be 
limited to the treatment of women with non-tubal ectopic pregnancies and those with 
residual ectopic trophoblast after salpingotomy. 
In conclusion, the results of our trial show that medical treatment with methotrexate of 
tubal ectopic pregnancies presenting with low serum hCG levels is not significantly 
better than placebo and its use in this group of women seems to offers no measurable 
health benefits. However, the actual observed reduction in failure rate with methotrexate 
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was nearly 30% and a larger study is required to detect a reduction of this magnitude as 
statistically significant.  In addition, further work may identify a subgroup of women 
with tubal ectopic pregnancies and hCG≥1500 IU/l in whom methotrexate may offer a 
safe and cost-effective alternative to surgery. 
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Figure captions 
 
Fig. 1  Trial profile. 
 
 
 
Table 1: 
Baseline characteristics of women with an ectopic pregnancy and serum hCG < 1500 
IU/l who were included in the trial.  
Covariate 
Single dose MTX Placebo P-values 
[test] (n=42) (n=38) 
Maternal age (years): mean(SD) 29(6.9) 30(6.7) 0.45[2] 
Ethnicity white: n(%) 17 (40) 25 (66) 0.02[1] 
Ethnicity black: n(%) 16 (38) 9 (24) 0.17[1] 
Ethnicity other/mixed: n(%) 9 (21) 4 (11) 0.19[1] 
Primigravida: n(%) 22 (52) 21 (55) 0.80[1] 
Parity: Quartiles 0-0-1 0-0-1 0.84 [3] 
Previous miscarriage: n(%) 10 (24) 9 (24) 0.59[1] 
Previous ectopic: n(%) 3 (7) 4 (10) 0.48[1] 
80 patients 
randomised
42 allocated to MTX
36 women treated 
with MTX
32 successful
4 surgical 
intervention
6 women declined 
trial intervention 
after randomisation
2 successful
3 surgical 
intervention
1 lost to follow up
38 allocated to 
placebo
3 women declined 
trial intervention 
after randomisation 
3 successful
35 women treated 
with placebo
26 successful
9 surgical 
intervention
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Smoker: n(%) 14 (33) 15 (39) 0.57[1] 
Gestational age (weeks): mean(SD) 6.9 (1.6) 7.0 (2.1) 0.62[2] 
Ectopic pregn. diameter (mm):  
mean(SD) 11.4 (6.9) 13.0 (7.2) 0.31
[2] 
Ultrasound morphology of ectopic pregnancy  
      Gestational sac: n(%) 23 (55) 12 (32) 0.04[1] 
      Inhomogenous solid mass: n(%) 19 (45) 26 (68) 
Baseline serum hCG (IU/l): Quartiles 238-465-914 189-405-784 0.34[3] 
Baseline Serum Progesterone 
(nmol/l): Quartiles 8 - 18- 28  7-14-28 0.37
[3] 
[1] Chi-sq; [2] two-sample t [3] Mann-Whitney 
 
 
 
 
 
 
Table 2: 
Primary and secondary outcomes of women with an ectopic pregnancy and hCG < 1500 
IU/l in a randomised double blind trial of methotrexate versus placebo 
 
Outcome Single dose 
MTX 
(n=41) 
Placebo 
(n=38) 
P* 
Uneventful decline in hCG (%)(95%CI) 34 (83)(72-
95) 
29 (76)(61-
87) 
0.61 
Surgical intervention 7 (17) (6-29) 9 (24)(13-
39) 
0.43 
Indication for surgery:    
Abdominal pain & evidence of blood 
in               pelvis on USS 
6 2  
Abdominal pain alone 0 2  
Rising hCG 1 5  
Blood transfusion 0 1 0.29 
 
* Χ2 without Yates correction and two tailed p value 
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